Our partner Edesa Biotech announced positive Phase 2 Data for the licensed anti-TLR4 monoclonal antibody in hospitalized COVID-19 patients
GENEVA, SWITZERLAND/ SEPTEMBER 20, 2021 /
In April 2020 Edesa Biotech and Light Chain Bioscience entered a license agreement for a clinical stage anti-TLR4 monoclonal antibody developed by Light Chain Bioscience. Edesa has been evaluating this antibody, named EB05, in a Phase 2/3 clinical trial as a single-dose treatment for hospitalized COVID-19 patients. The study was recently unblinded due to strong efficacy signal for 28-day mortality endpoint and critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over Standard of Care.
